{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK and SABRINA TAVERNISE", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}, {"rank": 2, "role": "reported", "firstname": "Sabrina", "organization": "", "lastname": "TAVERNISE"}]}, "abstract": "Valeant Pharmaceuticals International has outperformed its rivals in industry due in large part to executive J Michael Pearson's aggressive practice of buying up existing drugs and then raising prices on them significantly, but tactic has drawn ire of consumers and attention of regulators; focus of regulators has many in industry worried, as many companies employ similar tactic, though not to extreme Valeant does.", "type_of_material": "News", "word_count": "1668", "lead_paragraph": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "pub_date": "2015-10-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers", "print_headline": "A Drug Company&#8217;s Price Tactics Pinch Insurers and Consumers"}, "snippet": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "multimedia": [{"height": 126, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}], "blog": [], "_id": "5610f8bd38f0d85cd9760cec", "source": "The New York Times"}